Scaledbiolabs.com Website Review

We accelerate discovery and translation of cell therapies, to improve quality of life through regenerative medicine. relieving R&D bottlenecks and simplifying manufacturing pipelines Our Discovery Engine provides an unprecedented window into cell-driven biology. Microfluidic-enabled technology allows inputs to be combinatorially multiplexed to generate tens of thousands of experimental conditions End-to-end as*ay automation, enabled by cloud-directed robotics increases experimental reproducibility, performance whilst reducing Multi-dimensional, single-cell resolution data is rapidly turned into actionable results or cycled back through the process for enhanced Our Discovery Engine is enabling leading biotech and pharmaceutical companies to develop novel and optimal cell-based products and processes, simplifying manufacturing, reducing time to market, and improving clinical outcomes. Our internal, CIRM-funded program focuses on developing clinical grade iPSC-derived dopaminergic neurons as a curative cell therapy for the more than 10 million patients suffering from Parkinson’s disease.. DEFINING NEW STEM CELL DIFFERENTIATION STRATEGIES OPERATIONAL. inter-disciplinary experience drawn from around the world Drew Titmarsh is a trained chemical and biological engineer who designs and builds technology to understand the processes that drive the regeneration of human cells and tissue. He is the core developer of the microbioreactor array technology which is the workhorse platform of Scaled Biolabs. He has coordinated multidisciplinary projects at the Australian Institute for Bioengineering and Brendan Griffen has lead several large, data-driven projects in the fields of computational cosmology, astrophysics and theoretical physics at leading institutes across the USA, UK, Germany and Australia. Having completed his postdoctoral research at MIT's Kavli Institute For Astrophysics & Space Research, he now builds the an*lytical backend behind Scaled Biolabs' high-throughput wet lab